Key facts
- Notable investors include Hangzhou Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Neurotrace
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurotrace are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurotrace
Manufacturer of neurodiagnostic and neurophysiological testing equipment designed to support clinical and research applications in neuroscience. The company produces EEG systems, evoked potential devices, nerve conduction testing instruments, and related diagnostic hardware, enabling hospitals, research institutions, and clinical laboratories to conduct neurological assessments, monitor brain function, and support patient diagnosis with accurate electrophysiological data.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2022
- Employees
- 39
- Website
- neurotrace.net/
- Ownership
- Privately Held (backing)
Neurotrace doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurotrace shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurotrace in its N-PORT filings yet. We sweep new filings monthly.